Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; George, S.; Scheffold, C.; Wang, P.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K.

dc.contributor.author	Bedke, Jens
dc.date.accessioned	2025-02-04T07:10:38Z
dc.date.available	2025-02-04T07:10:38Z
dc.date.issued	2024
dc.identifier.issn	2059-7029
dc.identifier.uri	http://hdl.handle.net/10900/161573
dc.language.iso	en	de_DE
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.esmoop.2024.102994	de_DE
dc.subject.ddc	610	de_DE
dc.title	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20241001000000_01741
utue.personen.roh	Powles, T.
utue.personen.roh	Burotto, M.
utue.personen.roh	Escudier, B.
utue.personen.roh	Apolo, A. B.
utue.personen.roh	Bourlon, M. T.
utue.personen.roh	Shah, A. Y.
utue.personen.roh	Suarez, C.
utue.personen.roh	Porta, C.
utue.personen.roh	Barrios, C. H.
utue.personen.roh	Richardet, M.
utue.personen.roh	Gurney, H.
utue.personen.roh	Kessler, E. R.
utue.personen.roh	Tomita, Y.
utue.personen.roh	Bedke, J.
utue.personen.roh	George, S.
utue.personen.roh	Scheffold, C.
utue.personen.roh	Wang, P.
utue.personen.roh	Fedorov, V.
utue.personen.roh	Motzer, R. J.
utue.personen.roh	Choueiri, T. K.
dcterms.isPartOf.ZSTitelID	Esmo Open	de_DE
dcterms.isPartOf.ZS-Issue	Article 102994	de_DE
dcterms.isPartOf.ZS-Volume	9 (5)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE